Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE We have identified the TAF/FGF5/FGFR2/c-Src/HER2 axis as an escape pathway responsible for HER2 targeted therapies resistance in breast cancer which can be reversed by FGFR inhibitors. 31699826 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane. 31841262 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE A retrospective series of 686 ER+/HER2- BC were reclassified using AJCC 2018, and in the group of 521 patients for which AJCC 2018 recommends molecular evaluation, we assessed the prognostic efficacy of a prognostic stage enriched by Ki67 (Ki67-PS), considering Ki67 <20% an alternative to recurrence score <11 provided by Oncotype DX. 31780778 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE Clinical Validation of BCT Scores With Prognostic Factors in Hormone Receptor-positive, HER2-negative Early Breast Cancer. 31662548 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE Moreover, we found that there were 33 gene locus mutations of 8 genes including AKT1, APC, BRAF, CDKN2A, KRAS, PTEN, PIK3CA and TP53, but difference was not statistically significant (P > 0.05) when compared these gene mutations (except for PIK3CA) in each groups according to the histological classification of breast cancer and the ER/PR/HER2 classification. 30443844 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 AlteredExpression disease BEFREE In addition, by using human epidermal growth factor receptor 2 (<i>HER2</i>) as a model, we quantified individual <i>HER2</i> mRNA molecules in clinical breast cancer FFPE tissue sections and demonstrated its potential to resolve FISH-equivocal cases. 31782306 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE The HERmione study showed that, in a real-life setting, the safety of SC trastuzumab administered in HER2-positive eBC patients is consistent with data reported from previous clinical trials, without new safety concerns or QoL deterioration. 31670262 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 AlteredExpression disease BEFREE Expression of androgen receptor in primary breast carcinoma and its relation with clinicopathologic features, estrogen, progesterone, and her-2 receptor status. 31603099 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE Compared with non-carriers, PALB2 pathogenic mutation carriers developed breast cancer at a younger age (47.52 years vs. 51.35 years, p = 0.016) and were more likely to have triple-negative (24.1% vs. 13.4%, p = 0.022) or HER2 negative (87.0% vs. 74.2%, p = 0.031) breast cancer and large breast tumors (> 2 cm) at diagnosis (72.2% vs. 57.0%, p = 0.024). 31768816 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE Breast cancer with microcalcifications was significantly more positive for human epidermal growth factor receptor 2 than those without microcalcifications (48% vs. 22%, P = .018). 31255548 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE Sensitive and precise detection of ER, PR, and HER2 is of great significance for the diagnosis of breast cancer. 31665670 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE The potential markers of endocrine resistance among HR+ /HER2+ breast cancer patients. 31209793 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE These results support the classification of HER2+ BC into two major subgroups, LH-high and NLH, based on tumour morphology and immune response; LH-high proliferates via scirrhous and/or spiculated growth with a central scar, while the primary proliferation pattern of NLH is based on in situ carcinomas containing comedo necrosis with noticeable TILs and healing. 31554015 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE Transferred-tissue Microarray for Fluorescence In Situ Hybridization Test for Human Epidermal Growth Factor Receptor 2 in Breast Cancer. 30653031 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors. 31582515 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE In addition, TLR3 and TLR9 displayed significantly different expression levels in ER‑/PR‑negative breast cancer compared with the control tissues, while TLR5 expression was significantly reduced in HER2‑enriched breast cancer. 31789409 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE EpCAM (epithelial cellular adhesion molecule) and HER2 (human epidermal growth factor receptor 2) are two main circulating tumor cell (CTC) subsets in HER2+ breast cancer patients. 31583566 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE Here, we apply this approach to human epidermal growth factor receptor 2 (HER2)-expressing breast cancer by engineering exosomes through genetic display of both anti-human CD3 and anti-human HER2 antibodies, resulting in SMART-Exos dually targeting T cell CD3 and breast cancer-associated HER2 receptors. 31843452 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 AlteredExpression disease BEFREE Overexpression of HO-1 in HER2-expressing SKBR3 breast cancer cells resulted in reduced sensitivity to both pan-HER family kinase inhibitors sapatinib and lapatinib. 31705351 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE The aim of the present study is to elucidate the anticancer effect of its 6 α-hydroxy-4[14], 10[15]-guainadien-8β, 12-olide (SRCP1) against HER-2 positive subtype of breast carcinoma. 31678110 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE Although the role of HER2 and trastuzumab in oxidative stress is not yet completely understood, we suggest that trastuzumab may be a suitable agent for treatment in patients with HER2-enriched breast cancer in a non-oxidative chemotherapy scheme, with acceptable responses and no triggering hemolytic crisis. 31260379 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE Triple-negative (TN) breast cancer (testing negative for estrogen, progesterone, and Her2 receptors) has elevated GLS protein levels and reportedly depends on exogenous glutamine and GLS activity for survival. 31541193 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE In 2013, HER2 results were evaluated using two sets of four different breast cancer specimens in five laboratories. 31424659 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE Many studies have demonstrated that the extracellular domain of human epidermal growth factor receptor 2 (HER2 ECD) level in serum can act as a breast cancer biomarker and serve as a monitoring neoadjuvant therapy of breast cancer. 31790576 2020
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.600 Biomarker disease BEFREE Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with backbone endocrine therapy have markedly improved progression-free survival and overall survival over endocrine therapy alone in advanced hormone receptor-positive, HER2-negative (HR<sup>+</sup>/HER2<sup>-</sup>) breast cancer and are the standard of care in the first- or second-line setting. 31780379 2020